Full Text
EE274 Is It Worthwhile for an Orphan Product to Expand Indications Given the Risk of Medicare Negotiation?

Abstract

Authors

W. Derrickson L. Leybova N. Soni E. Jamali

Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×